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Abstract
Background: The BIO14.6 hamster is an excellent animal model for inherited cardiomyopathy, because of its lethal and well-
documented course, due to a spontaneous deletion of delta-sarcoglycan gene promoter and first exon. The muscle disease
is progressive and average lifespan is 11 months, because heart slowly dilates towards heart failure.
Methodology/Principal Findings: Based on the ability of adeno-associated viral (AAV) vectors to transduce heart together
with skeletal muscle following systemic administration, we delivered human delta-sarcoglycan cDNA into male BIO14.6
hamsters by testing different ages of injection, routes of administration and AAV serotypes. Body-wide restoration of delta-
SG expression was associated with functional reconstitution of the sarcoglycan complex and with significant lowering of
centralized nuclei and fibrosis in skeletal muscle. Motor ability and cardiac functions were completely rescued. However,
BIO14.6 hamsters having less than 70% of fibers recovering sarcoglycan developed cardiomyopathy, even if the total
rescued protein was normal. When we used serotype 2/8 in combination with serotype 2/1, lifespan was extended up to 22
months with sustained heart function improvement.
Conclusions/Significance: Our data support multiple systemic administrations of AAV as a general therapeutic strategy for
clinical trials in cardiomyopathies and muscle disorders.
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Introduction
Limb-girdle muscular dystrophies 2C-2D-2E-2F (LGMD2C–
2F) are classified as ‘‘sarcoglycanopathies’’. They have typically a
childhood onset and represent the most severe forms of LGMD,
often associated with cardiomyopathy [1]. Alpha-, beta-, gamma-,
and delta-sarcoglycan are arranged at the muscle membrane in the
form of a heterotetrameric dystrophin-associated complex at a
1:1:1:1 ratio. When one component is absent, the other
sarcoglycans are displaced and degraded, since the stability of
the complex is impaired. Sarcoglycan complex is also secondarily
reduced in Duchenne muscular dystrophy (DMD), when dystro-
phin is missing [2], indicating that DMD muscle suffers from
combined dystrophin and sarcoglycan complex deficiencies [3].
The BIO14.6 hamster displays absence of delta-sarcoglycan from
the muscle membrane, followed by the deficiency of alpha, beta
and gamma sarcoglycan, reproducing the human LGMD2F
phenotype [4]. This animal model was generated in 1962, when
Homburger fixed by repeated inbreeding a spontaneous trait of
Syrian hamster characterized by muscular dystrophy and
cardiomyopathy [5]. All the other cardiomyopathic hamsters are
derived from this first strain, among which TO-2, UM-X7.1,
presenting different types of cardiomyopathy. All strains carry the
same homozygous 24-kb deletion of the delta-sarcoglycan (d-SG)
gene promoter and first exon [6]. Interestingly, Zhu et al. used for
gene therapy the TO-2 hamster strain that show a shortened
lifespan caused by rapid congestive cardiomyopathy without
hypertrophy, with minimal muscle disease [7]. This study was
completed after 48 weeks and single AAV treatment was effective.
We chose to study the efficacy of gene therapy on the original
BIO14.6 hamster, since it is the best characterized strain with over
1,000 citations, to date. Disease stages are uniform within BIO14.6
strain due to the homogeneous genetic background. Differently
from the dystrophin-deficient mdx mouse that shows muscle
regenerative capacity and lives 80% of wild type (WT) mice [8],
the average lifespan of BIO14.6 hamsters is 11 months (about 40%
of the WT hamster), because the heart dilation slowly progresses to
an ejection fraction of 20–30%, leading to heart failure. In
addition, the BIO14.6 hamster displays a continuous loss of muscle
strength in the course of the life and has no successful muscle
PLoS ONE | www.plosone.org 1 March 2009 | Volume 4 | Issue 3 | e5051regeneration. The heart pathology observed in this animal model
is similar to human X-linked cardiomyopathy, in which the heart
dystrophin is absent [9].
Adeno-Associated Viruses (AAVs) are non-pathogenic single-
stranded DNA parvovirus. Each end of the single-stranded DNA
genome contains an inverted terminal repeat that is mandatory for
replication and packaging. The promoter and transgene cDNA
are inserted between the two inverted terminal repeats, with Rep
and Cap provided in trans. Because there are no viral genes in the
recombinant AAV, vector toxicity should be avoided. All the AAV
used for gene therapy studies are transcapsidated: that is to
package an AAV genome containing an ITR from one serotype
(AAV2) into the capsid of another serotype (i.e. AAV 2/1): this
allows expanding the repertoire of AAV for better targeting of cell
types [10, and references therein]. AAV1 and AAV6 are very
similar with six amino acid differences, AAV8 was isolated from
rhesus monkey, while AAV9 from human tissues. AAV-mediated
gene transfer to muscle demonstrated long-term persistence. In
hemophilia B dogs, factor IX (FIX) was recovered .4 years
following AAV2-FIX injection in both muscle biopsies and
circulation. Haemophilia B patients receiving intramuscular
injections of AAV encoding FIX were shown to have consistent
local expression of FIX up to 3.7 years following delivery [11].
Interestingly, systemic administration of AAV 2/1, 2/6, 2/8 or 2/
9 resulted in efficient body-wide muscle transduction. This can be
suitable for treating genetic disorders affecting all muscles [12–14].
We used male BIO14.6 hamsters to test AAV serotypes 2/1, 2/8
and 2/9. We compared different protocols of systemic gene
delivery and monitored the progression of heart and muscle
disease for each group of injected animals. We observed a general
improvement in each group of treated animals, in particular in the
hamsters injected at 2 weeks with serotype 2/8. To test long-term
transgene expression, we also used double AAV injections with
two different serotypes to elude immune reaction. Hamsters
received the serotype 2/8 at 2 weeks and 2/1 at 5 months of age.
We observed a normal lifespan in the double injected hamsters,
due to persistent rescue of skeletal muscle and heart structure and
function.
Results
To compare the efficiency of alternative protocols for systemic
gene delivery into hamsters, we measured the following param-
eters at different times after the treatment: i) degree and
distribution of human d-SG expression; ii) expression of the other
components of the sarcoglycan complex; iii) muscle pathology; iv)
cardiac and skeletal muscle function (Figure 1). All animals were
male.
Protocol design
The parameters varied in the alternative protocols were: 1)
timing of delivery; 2) AAV serotypes; 3) number of injections; 4)
route of injection. The AAV dose was kept at 4610
‘13 GC/kg for
all the experiments.
Figure 1 shows the experimental timelines of six different groups
of hamsters.
Group 7w 2/1: we injected AAV2/1-CMV-hSCGD into three
7-week-old (approximately 60 g) BIO14.6 hamsters through the
jugular vein.
Group 2w 2/1: it comprises three BIO14.6 hamsters intraper-
itoneally treated at two weeks of age (approximately 15 g) using
AAV2/1-CMV-hSCGD.
Group 2w 2/8: it includes nine BIO14.6 hamsters intraperito-
neally treated at two weeks of age with AAV2/8-CMV-hSCGD.
Group 2w 2/9: it consists of ten BIO14.6 hamsters intraper-
itoneally treated at two weeks of age with AAV2/9-CMV-
hSCGD.
Group 2/1+2/8: it includes three hamsters intraperitoneally
injected at 2 weeks of age with AAV2/1-CMV-hSCGD and then,
at 5 months of age, with AAV2/8-CMV-hSCGD via the jugular
vein.
Group 2/8+2/1: it includes six hamsters intraperitoneally
injected at 2 weeks of age with AAV2/8-CMV-hSCGD and
then, at 5 months of age, with AAV2/1-CMV-hSCGD via the
jugular vein.
The AAV serotype of the second injection was always changed
to avoid any anti-capsid immune response. We verified and
excluded the presence of neutralizing antibodies against AAV2/1
or AAV2/8, in groups 2/1+2/8 and 2/8+2/1 respectively, prior
to the second AAV administration. As expected, we did not
observe any response against d-SG that is expressed at about 3%
in BIO14.6 hamsters, since an alternative upstream promoter is
activated. On the other hand, sequence conservation between
human and hamster d-SG is 98%.
Expression of the SG complex
To test the expression of d-SG, we analyzed tissue extracts by
western blotting (Figure 2A), using a monoclonal Ab (NCL-d-
SARC) against human d-SG (Figure 1, stop signs). Since we
delivered the human cDNA for the delta-sarcoglycan we can easily
distinguish transgene protein from traces of endogenous hamster
protein. The NCL-d-SARC cannot detect the hamster protein in
WT animals, as it recognizes a human-specific N-terminal epitope
(Figure 2B). We observed that the delta-sarcoglycan expression
was faint in the 7w 2/1 hamsters (not shown). On the other hand,
the expression of d-SG was reproducible and evident in the
muscles of 2w 2/8 hamsters (heart, gastrocnemius, quadriceps and
diaphragm). The expression was variable in the skeletal muscles of
2w 2/1 and 2w 2/9 hamsters. In heart, the expression of d-SG was
weak or completely absent when we used AAV2/1. This result is
in agreement with what has been observed with AAV2/6 that is
very closely related to AAV2/1 [12]. In contrast, the heart of
BIO14.6 expressed very high levels of d-SG when we used
serotype 2/8. Similar expression levels were seen in the 2/8+2/1
hamsters, but not in the 2/1+2/8 group. This result was evident
up to 22 months of life (not shown). The d-SG was expressed in the
liver of some animals injected with serotype 2/8, but this
expression did not cause any apparent hepatic abnormality at
the histological level (not shown). No expression was observed in
lung (Figure 2A), spleen, kidney and testis with any of the vectors
used (not shown). The d-SG expression level in the 2/8+2/1 and
2w 2/8 groups was in muscle and heart 3–46higher than in the
normal Syrian hamsters.
The recovery of the other components of the sarcoglycan
complex was analyzed by indirect immunofluorescence staining.
Antibodies against a-SG (NCL-a-SARC), b-SG (NCL-b-SARC),
c-SG (NCL-g-SARC) and human d-SG (NCL-d-SARC) (Fig 2C–
I) on 9-m sections from heart, quadriceps, gastrocnemius,
diaphragm, and tongue were used.
Double immunofluorescence staining with both rabbit anti d-
SG and mouse anti-a-SG or b-SG Ab showed a complete co-
localization on muscle fibers (Figure 2J). The expression of the
human d-SG was constantly associated with the re-expression of
the other sarcoglycan proteins belonging to the complex in all
groups of animals. We also calculated the expressing fiber
percentages in different tissues. The human d-SG expressing
fibers were on average 50.3% in the 7w 2/1 group, 68.2% in the
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2/9 hamsters and the 80.0% in the 2/8+2/1 hamsters (Figure 2K).
Muscle pathology
To assess rescue of normal muscle structure, we first considered
the percentage of centralized nuclei. In a normal hamster muscle,
some rare nuclei can be observed at the center of cells (3%). These
are regenerating fibers. In BIO14.6 hamsters, up to 60% of fibers
have centralized nuclei. We counted the centralized nuclei of three
different sections from quadriceps, gastrocnemius, diaphragm, and
tongue. At least three hamsters for each group were evaluated at
1.5, 3 and 6 months respectively, comparing average values with
age-matched WT and BIO14.6 hamsters We obtained an
improvement in the 7w 2/1 (33.6%), 2w 2/1 (19.2%) and 2w
2/9 (37.6%) groups, compared with the untreated hamsters, in
which the average percentage of centralized nuclei was 46.9%
(Figure 3A). A much stronger reduction was observed in the 2w 2/
8 (13.0%) and 2/8+2/1 (10.2%) groups. The percentage of
centralized nuclei in 2w 2/8 and 2/8+2/1 groups were
significatively different from the BIO14.6 hamsters (p value=
0.000038).
We analysed the cardiac and skeletal muscle structure
evaluating necrotic areas by hematoxylin-eosin staining
(Figure 3B) and the presence of fibrosis by Masson’s Trichrome
procedure (Figure 3C). Since fibrotic areas appear in the course of
the life, we evaluated the presence of fibrotic areas at 7 months of
age for each group of hamsters. The 7w 2/1 hamsters showed
large areas of necrosis and calcification, similar to the surviving
untreated BIO14.6 at the same age. The best results were obtained
in the 2w 2/8 and 2/8+2/1 animals, in which we noted the total
absence of fibrotic and calcified areas and the lowest percentage of
centralized nuclei. We found cardiomyocyte degeneration,
necrosis and pronounced fibrosis in the untreated hamsters, but
also in the 7w 2/1 hamsters.
Non-invasive cardiac monitoring
To monitor the major cardiac functional indexes, we used serial
echocardiographies. We measured the left ventricle end-systolic
and end-diastolic dimensions (LVD and LVS), the left ventricle
posterior wall thickness, (indexes of cardiac hypertrophy). We
calculated the ejection fraction (EF%) that is one of the most
significative parameter to evaluate heart failure. The data were
Figure 1. Timelines of the experimental procedures for the different groups of hamsters. w: weeks; m: months; WT: Wild-type hamsters;
NT: BIO14.6 hamsters not treated; i.p. : intraperitoneally; i.v. : intravenously; 7w 2/1: hamsters injected at 7 weeks of age with d-SG by AAV 2/1; 2w 2/1,
2w 2/8, 2w 2/9: hamsters injected at 2 weeks by AAV 2/1, 2/8 and 2/9, respectively; 2/1+2/8: hamsters injected at 2 weeks by AAV 2/1 and at 5 months
with d-SG using AAV 2/8; 2/8+2/1: hamsters injected at 2 weeks by AAV 2/8 and at 5 months using serotype 2/1. The timeline stops when all the
hamsters of the group are dead.
doi:10.1371/journal.pone.0005051.g001
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detected significant improvement in all the groups of treated
hamsters, and above all in the 2w 2/8 and 2/8+2/1 hamsters
(Figure 4A and 4B).
The ejection fraction in both 2w 2/8 and AAV2/8+2/1 groups
of hamsters was significatively different from the group of
untreated BIO14.6 hamsters (p value=0.0000028).
We sacrificed some animals from each group at 7 months of age
and removed the hearts. We observed enlarged gross heart
morphology in the 7w 2/1 and 2w 2/1 animals, in a similar
fashion with age-matched untreated hamsters. A very small
increase in the heart size was in the 2w 2/8 hamsters, and a
normal size in the 2/8+2/1 hamsters, similar to WT hamsters
analysed at the same age (Figure 4C).
Skeletal muscle function
To further confirm the skeletal muscle function recovery,
animals for each group were tested by forced run on the rota-rod
at a fixed speed (1.6 m/min for 45 minutes). At 6 months of age,
BIO14.6 show reduced motility in the cage; in contrast, treated
animals preserved spontaneous motility. On average, the WT
hamsters did not fall off the rota-rod and never stopped running
before the end of the test. The BIO14.6 animals could hardly run
on the rota-rod, and stopped running more than 10 times during
the exercise. The 2w 2/8 and 2/8+2/1 were indistinguishable
from the WT (Movie S1). These data suggest that systemic delivery
of human d-SG by AAV vectors significatively ameliorated the
cardiomyopathy and the muscular dystrophy in younger hamsters
BIO14.6 than in the older ones and that the double injection can
further improve the rescue of the phenotype in these animals.
Long term study
To investigate whether the observed rescue was long-lasting, we
also measured echocardiographic parameters in the surviving 12
month-old animals. We recalculated the ejection fraction (EF%).
While all animals of the 2/8+2/1 group were still alive with
sustained maintenance of good values of the ejection fraction
(70.7% on average), in the group of 2w 2/8 two animals survived
with an average ejection fraction of 59.8% (Figure 5A).
Finally, we calculated the survival curves respectively of the
BIO14.6, 2w 2/8 and 2/8+2/1 animals and we found that percent
survival as a function of time was significatively different (p,0.002)
(Figure 5B).
Discussion
We show that systemic treatment of muscular dystrophy and
cardiomyopathy is feasible and efficacious with either a single or
two sequential injections of AAV expressing delta sarcoglycan.
Muscle tissue represents about 40–50% of total body mass. In
severe muscular dystrophies, respiratory failure [15] and/or heart
failure [16] can be the causes of premature death. In addition,
patients suffer from asymmetries in strength between reciprocal
muscles that cause widespread joint and spine deformities
requiring timely orthopaedic surgery [17]. Therefore, muscular
dystrophies should be regarded as systemic disorders, and the
rescue of single muscles can hardly obtain a significant therapeutic
outcome.
An ideal therapy should be effective in 1) recovering balanced
strength in all muscles; 2) preventing heart lesions; 3) improving
respiratory function; 4) avoiding adverse immune reaction; 5)
lasting along the entire lifespan. This compelled us to drive our
research efforts towards testing the most effective systemic
treatments.
AAV are among the most promising vectors for gene delivery in
vivo, because they show widespread and sustained transgene
expression after a single administration. AAV also showed efficient
body-wide transduction capabilities when injected systemically
using an intraperitoneal route in newborn animals. Novel
serotypes have been introduced, each with peculiar tissue tropism.
Muscle-targeting serotypes include AAV2/1, 2/5, 2/6, and 2/8
that show a transduction efficiency in mice up to 500 times greater
than AAV2/2 [7,18–22]. Previous reports evidenced the ability of
AAV2/9 to transduce muscular tissues and in particular the
myocardium, at 5- to 10-fold higher levels than AAV2/8 [14,23].
One main limitation of AAV vectors was represented by its
packaging ability that is restricted to 4.7 kb. This is a value
compatible with the introduction of a small/medium-sized cDNA,
such as delta-sarcoglycan that is 0.9 kb long. A recent paper
demonstrated that vectors with AAV5 and AAV1 capsids can
incorporate efficiently up to 8.9 kb of genome expanding the
therapeutic potential of AAV vectors [24]. This could become
suitable for dystrophin cDNA that can be further deleted to a
compatible size without loss of function (mini-dystrophin) [25].
Sarcoglycan gene defects are an optimal model to test gene
delivery, because the true function of the transgene can be
followed through the recovery of the other sarcoglycan compo-
nents [7,26–28].
Zhu et al. obtained straightforward results using a single AAV8
injection in a related hamster (TO-2) that show a rapidly
congestive cardiac phenotype [7]. This work constitutes the basis
to test alternative AAV delivery strategies for long-term efficacy.
To optimize gene delivery protocols, reproducibility is a ‘‘must’’,
since animals may be dissimilar in disease course and/or in disease
rescue [29]. We chose the male BIO14.6 Syrian hamster model for
three main reasons: a) it is a genetically homogeneous strain, since
it has a 35-year long inbreeding story by Bio-Breeders [30]; b) it
has a reproducible schedule of both cardiomyopathy and muscular
dystrophy, documented by a very large number of studies; c) the
Figure 2. Expression and localization of the injected d-SG. (A) Expression of d-SG assessed by WB analysis in heart (H), quadriceps (Q),
diaphragm (D), Gastrocnemius (G), Liver (Li) and lung (Lu) respectively of 2w 2/1, 2w 2/9, 2w 2/8 and 2/8+2/1 groups of hamsters. (B) WB performed
using a polyclonal antibody against d-SG and a monoclonal antibody against human d-SG, respectively on heart and quadriceps of 2w 2/8, WT
BIO14.6 hamsters. The expression and the localization, as well as the restoration of the SG complex was assessed through immunofluorescence (IF)
staining respectively on heart, gastrocnemius and tongue of WT and BIO 14.6 not treated (C and D), compared with BIO14.6 hamsters that received
alternative treatment protocols (E–I). IF were carried out by monoclonal antibodies against a-, b-, and human d-SG respectively on 7w 2/1; 2w 2/1, 2w
2/8 and 2w 2/9; 2/8+2/1. The co-expression of SGs was determined with co-IF staining on several muscles of injected hamsters. Examples of co-IF
staining on double injected hamsters (2/8+2/1) and 2w 2/9 hamsters are reported (J). Monoclonal antibody against alpha-SG, beta-SG or gamma-SG
together with polyclonal antibody against delta-SG were used to test the co-expression of the proteins on the sarcolemma. They were stained
respectively using secondary antibodies conjugated with Cy3 or FITC fluorochrome. On the left of the figure the merge shows the co-localization of d-
SG with a-, b-o rc-SG. Original magnification, 206. (K) We calculated the percentage of fibers expressing d-SG in the differently injected groups of
hamsters. The percentages were evaluated estimating the number of expressing fibers in cryosections of gastrocnemius, quadriceps and tongue of
each group of treated hamsters compared with BIO14.6. The number of the analysed hamsters are indicated in the figure. The bars represent the
mean6the standard error of the analysed animals.
doi:10.1371/journal.pone.0005051.g002
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much, to follow long-term disease progression. Heart disease is
similar to the dilated cardiomyopathy of human muscular
dystrophies [31,32] and can be followed during the entire lifespan
of the animal by serial echocardiographies.
The initial approach was to compare different protocols, to
establish the best methodology for systemic delivery of d-SG. The
parameters tested were: the route of injection, the age and the
number of injections, and the AAV serotypes.
1. The route of injection.
We injected adult hamsters systemically into the jugular vein,
whilst the young animals were injected intra-peritoneally,
assuming this way as systemic according to Xiao [7]. We observed
that the serotype 2/8 was capable of delivering d-SG in muscle
and heart in both cases while the serotype 2/1 did not reach the
heart efficiently.
2. The age of injection.
Previous studies have assessed the efficiency of injecting AAV
vectors expressing d-SG under the control of the muscle specific
synthetic promoter SP instead of the CMV promoter in both
young (10 days old) and adult hamsters [33]. We administered the
same dosage of AAV2/1 expressing the d-SG under the control of
the CMV promoter both into adult hamsters and into newborn
ones. When we treated newborn hamsters, we observed a dramatic
change for each histological parameter considered, i.e. the
percentage of fibers expressing d-SG, the percentage of centralized
nuclei, and the absence of large fibrotic or necrotic areas. This
observation suggests that the injection in younger hamsters is more
efficient probably because, in adult animals, necrotic and fibrotic
areas may reduce the transduction into the muscle.
3. AAV serotypes.
We tested different serotypes, because there are conflicting
results on the transduction ability of AAV serotypes to infect
cardiac and muscular tissues (and these are mainly referred to
mice) [7,11,12,23] We used AAV2/1, AAV2/8, and AAV2/9,
also in combination, performing two injections at different times
into the same hamsters. We observed the best transduction
efficiency in the hamster treated at 2 weeks with the AAV2/8
serotype, which showed high percentage of expressing fibers, low
percentage of centralized nuclei, absence of necrotic or fibrotic
areas and a general improvement in each echocardiographic
parameter. Longer-lasting results were obtained with the double
injection 2/8+2/1, since the survival curve was significatively
different from 2w 2/8 and untreated animals. This suggests that
the double treatment could maintain a longer expression of delta-
sarcoglycan. Interestingly, one of the BIO14.6 hamsters receiving
the double injection 2/8+2/1 lived up to 22 months (+100% of
expected lifespan). Furthermore, we observed that all the double
injected 2/8+2/1 hamsters were still alive at 16 months, showing
70% of ejection fraction. This percentage declined to 59.8% and
58.5% respectively, in two surviving 2w 2/8 and 2/1+2/8 animals
while the 2w 2/9 and the untreated hamsters at the same age were
dead. We also confirmed that the serotype 2/8 is the most efficient
of those tested for intraperitoneal delivery into newborn hamsters
[13]. We hypothesized that, after the first neonatal injection, the
degeneration of muscle to fibrocalcific/fibroadipous tissue was
prevented, thus a late injection with a different serotype could
result in a transduction of the surviving muscle and boost the
expression of the delta-sarcoglycan. This explains why the first
injection at 7w of AAV2/1 was less effective than that performed
at 5 months in 2w 2/8 hamsters.
Our results with serotype 2/9 are unsatisfactory and it was in
contrast with the previous observations on the ability of AAV2/9
in mice to transcend vasculature and transduce myocardium [14].
We showed that the 2w 2/9 hamsters showed much weaker
transduction than the 2w 2/8 animals and this result was
confirmed using different AAV preparations. One possible
explanation could be related to the intraperitoneal route of
administration [13]
To avoid cardiomyopathy it is necessary to have a sustained and
homogeneous distribution of the rescued fibers. This situation is
dissimilar from what happens for the skeletal muscle where levels
of about 30% of dystrophin are sufficient to avoid disease [34].
Interestingly, heterozygous carriers of dystrophin defects have no
skeletal muscle disease, but they show dilated cardiomyopathy
[35]. This is in contrast with the results of Bostick on mdx mice
[36]. It is possible that the penetrance of cardiac phenotype in
mice is lower than in human and hamsters. BIO14.6 hamsters
having less than 70% of fibers expressing delta-sarcoglycan
developed cardiomyopathy, even if the total amount of protein
measured by western blot analysis was in the normal range or 3–4-
fold above the normal range. This elevated expression did not
cause any problems for heart or muscle in contrast to what was
previously observed in transgenic mice bearing the d-SG S151A
allele [37].
This underscores the importance that patients receive homoge-
neously the missing protein; otherwise the infection will be
ineffective to rescue the phenotype.
The advantage of testing the efficacy of a second injection using
a second serotype is related to the possibility both of improving the
survival and extending the therapeutic window as was observed in
our experiments. Patients treated with single AAV may have a
second chance using a different serotype. This could be relevant
considering that ongoing human trials with proof-of-principle
intramuscular injections can produce life-long immunization
against AAV.
In conclusion we showed long term biochemical, morphological
and functional improvement in a rodent model of sarcoglycano-
pathy following AAV mediated body-wide muscle transduction.
This has important implication for therapies of life treatment and
incurable muscular dystrophies.
Materials and Methods
AAV vector construction and production
The human d-SG gene was cloned into the plasmid pAAV-
2.1CMV-EGFP. Recombinant AAV vector containing human
delta-sarcoglycan cDNA, driven by the cytomegalovirus (CMV)
promoter, were constructed by standard cloning protocols and
were packaged into AAV2/1, 2/8 and 2/9 serotypes. The
resulting pAAV2.1-CMV-delta-SG were transfected in sub-
confluent 293 cells along with the pAd-Helper and the pack
Figure 3. Gene delivery of delta-sarcoglycan through AAV vectors diminishes the percentage of centralized nuclei and the necrotic
and fibrotic areas in heart and muscle. (A) Percentage of centralized nuclei respectively in 7w 2/1, 2w 2/1, 2w 2/8, 2w 2/9 and 2/8+2/1 groups of
hamsters compared with BIO14.6 and WT hamsters. The bars represent the mean6the standard errors of the analysed animals. (B) Hematoxilin- Eosin
staining on cryosections respectively of heart, quadriceps and tongue of wild type, treated and BIO14.6 hamsters. The black gross arrows indicate
calcified and necrotic areas. The thin arrows underline the centralized nuclei. On the same groups of hamsters we performed Masson’s trichrome
staining on cryosection respectively of heart, quadriceps, tongue and gastrocnemius (C). The black gross arrows indicate fibrotic areas. All
cryosections were analysed at 7 months of life. Original magnification, 206.
doi:10.1371/journal.pone.0005051.g003
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previously [38]. The recombinant AAV2/8, 2/1 or 2/9 vectors
were purified by two rounds of CsCl, as described previously.
Vector titers, expressed as genome copies (GC/ml), were assessed
by real-time PCR (GeneAmp 7000 Applied Biosystem), as
described previously [39].
Animals and vector administration
All procedures on wild-type F1B and dystrophic BIO14.6
hamsters (Bio Breeders, Fitchburg, Mass) have been approved by
the relevant Local Committees for ‘‘Good Animal experimental
Activities’’.
Western Blotting
Muscle or other tissues were homogenized and lysed in a lysis
assay buffer (Urea 8M, SDS 4%, 125 mM Tris HCl pH 6.8). The
samples were separated on sodium dodecyl sulfate-10% polyacryl-
amide gel electrophoresis and transferred to nitrocellulose
membrane. After blocking in 10% non-fat dry milk in Phos-
phate-buffered saline (PBS-1X) buffer (10 mM Tris-HCl, 200 mM
NaCl, 0.05% NP 40, 0.05% TWEEN 20) for 1 h, the membranes
were incubated with primary antibodies in PBS-1X at room
temperature for 2 h. The monoclonal antibody recognizing a
human epitope of d-SG was used in this experiment with a 1:25
dilution. Following primary antibody incubation and rinses, the
membranes were incubated with the secondary antibody, goat
anti-mouse immunoglobulin conjugated with horseradish perox-
idase (Sigma), with 1:15,000 dilution in 0.5% dry milk and PBS-
1X buffer. After a 1-h antibody incubation and three washes with
PBS-1X buffer, the d-SG protein band was visualized with a
chemiluminescence reagent (Supersignal, WestPico, Pierce) and
exposed to X-ray film.
Histology
Muscle or other tissues were collected at 2, 3 or 6 months after
vector injection. Tissues samples were processed by cryosections at
7- to 10- mm thickness.
Hematoxylin-Eosin staining
Cryosections of muscular tissues were fixed in 4% PFA, then
washed in PBS-1X and then they were stained in hematoxylin for
4 minutes and eosin for 6 minutes. Then the cryosections were
dried in ethanol and at the end they were fixed in xylene and
mounted with EUKITT mounting (O. Kindler GmbH & CO).
Masson’s trichrome staining
Infiltrations of fibrotic tissue respectively in heart, gastrocnemi-
us, quadriceps and tongue were observed by Masson’s trichrome
staining. (9 mm of thickness). Cryosections of muscular tissues were
fixed in Bouin’s Solution at 56uC for 15 minutes, cooled and
washed in running tap water to remove yellow colour from section.
They were stained in Working Weigert’s Iron Hematoxilin
Figure 4. Morphologic and echocardiographic changes after gene delivery of delta-sarcoglycan in the differentially treated groups
of hamsters. (A) Percentage of the ejection fraction in the 8-month-old BIO14.6 of differently treated hamsters, compared with the untreated
BIO14.6 and the Wild Type F1B hamsters. The percentage calculated in the 2 w 2/8 and the 2/8+2/1 hamsters are significatively higher than the ones
evaluated in the other groups (p-value: 2.8489e-006). The number of the analysed hamsters are indicated in the figure. The bars represent the
mean6the standard error of the analysed animals. (B) Representative transthoracic left ventricular M-mode echocardiograms of 8-month-old BIO14.6
of differently treated hamsters, compared with the untreated BIO14.6 and the Wild Type F1B hamsters (C) The size of the heart of both 2w 2/8 and 2/
8+2/1 hamsters is comparable to the size of WT hamsters’ heart. Differently, the 7w 2/1 and the 2 w 2/9 groups show a very enlarged heart. The
images were acquired at 7 months.
doi:10.1371/journal.pone.0005051.g004
Figure 5. Long-term studies on surviving hamsters. (A) Histograms and standard errors of the mean of the ejection fraction (EF) percentage
measured on the hamsters survived over 12 months in the groups under study. The two leftmost histograms, respectively the average EF value of the
wild type F1B group (WT) and of the untreated BIO14.6, represent the two extremes of our measurements. The middle and the two rightmost
histograms show the rescue on the FE due respectively to the treatments 2w 2/8, 2/8+2/1 and 2/1+2/8. It is easy to see that each of the three
treatments is resulting in a gain of FE percentage and that in particular the 2/8+2/1 results to perform best. (B) Fleming-Harrington estimates of the
survival curves respectively of the 2w 2/8, 2/8+2/1 and BIO14.6 groups of hamsters. The log-ratio test revealed, with a p-value of 0.002, that these
three survival curves are significantly different.
doi:10.1371/journal.pone.0005051.g005
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and stained in Biebrich Scarlet- Acid Fucsin for 5 minutes, then
rinsed in deionized water, placed in Working Phosphotungstic\-
Phosphomolybdic acid solution for 5 minutes, stained in Aniline
Blue solution for 5 minutes and in acid acetic 1% for 2 minutes.
The slides were mounted with EUKITT mounting (O. Kindler
GmbH & CO).
Immunofluorescence
For immunofluorescence staining, the unfixed muscle cryosec-
tions were immediately blocked in 10% goat serum and
phosphate-buffered saline (PBS-1X) at room temperature for
1 h. Monoclonal antibodies (NCL-a-SARC, NCL-b-SARC, NCL-
g-SARC and NCL-d-SARC), respectively against a-SG, b-SG, c-
SG and d-SG were used (Novocastra Laboratories). a-SG, b-SG
and c-SG were diluted at 1:100; the monoclonal antibody against
d-SG was diluted 1:25; the polyclonal antibody to d-SG was
prepared in our laboratory
6. It was diluted 1:1000 in 10% goat
serum-PBS-1X and incubated with the cryosections for 1 h and
309 at room temperature. After three washes, the sections were
incubated with Cy-3-labeled antimouse or antirabbit secondary
antibodies respectively at 1:300 and 1:400 dilution in 10% goat
serum-PBS-1X (Jackson Immuno Research Laboratories). After
three washes, the samples were mounted in Vectashield mounting
with DAPI (Vector Laboratories). All sections were acquired under
a Zeiss Axioplan fluorescence microscope, using Axio Vision 4.5
software at a magnification of 206.
Echocardiographic Study
All hamsters received baseline echocardiograms under con-
trolled anesthesia and spontaneous respiration, using a Vivid 7
(GE VingMed, Horten, Norway) with a linear 13 MHz probe
(i13L). The anterior chest hair was removed using a shaver and the
hamsters were positioned in left lateral decubitus on a wooden
bench. Recordings were made under continuous ECG monitoring
by fixing the electrodes on the limbs.
Grey scale imaging
Grey scale images were recorded in a parasternal short axis
view at a depth of 2 cm. M-Mode tracings were recorded at the
level of the papillary muscles at a speed of 200 mm/s. Left
ventricular (LV) dimensions were measured from three consec-
utive cardiac cycles on the M-Mode tracings. The Teichholz
formula was used to calculate LV volumes: Pi*D3/6a (D J
diameter of the ventricle in short axis view; a J ellipticity factor.
An ellipticity factor of 1/3 was used, assuming that L J 3D (L J
total length of the ellipse). LVEF was calculated as LV end-
diastolic volume e LV end-systolic volume/LV end-diastolic
volume and expressed in %.
Statistics
We performed a one way analysis of variance (ANOVA) for
testing the effects of the grouping variable on the mean
respectively of the Ejection Fraction (EF) and of the observed
NC percentage (NC). We used a Fleming-Harrington test for the
analysis of the survival.
We performed a posterior multiple comparison test at level 0.05,
with a Bonferroni adjustment for multiplicity.
Supporting Information
Movie S1 Hamsters respectively not treated (lane 1), treated at 2
weeks with serotype 2/8 (lane 2) and double treated, 2/8+2/1
(lane 3), after 40 min of exercise at a constant speed.
Found at: doi:10.1371/journal.pone.0005051.s001 (12.32 MB
MPG)
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